Loading…
Patent Eligibility Restoration Act of 2025
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (34)
Referred to the House Committee on the Judiciary.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Copyright/Patent/Trademark
H.R. 1574: RESTORE PATENT RIGHTS ACT OF 2025; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM H.R. 3152: PATENT ELIGIBILITY RESTORATION ACT OF 2025; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM H.R. 3160: PREVAIL ACT; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM S. 708: RESTORE PATENT RIGHTS ACT OF 2025; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM S. 1546: PATENT ELIGIBILITY RESTORATION ACT OF 2025; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM S. 1553: PREVAIL ACT; PROVISIONS RELATED TO INTELLECTUAL PROPERTY AND STRENGTHENING THE COPY RIGHT AND PATENT SYSTEM
Client expense: $1,120,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2026 · third_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) ---Patentability of AI Assisted Inventions Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act ---Department of Commerce Patent Valuation Fee Proposal ---PTAB Reform ---PTO Proposed Rules on Terminal Disclaimer Practice ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China
Client expense: $2,560,000 · Firm income: Not reported
2026 · third_quarter · Copyright/Patent/Trademark
S. 1367/H.R.2794, NO FAKES Act of 2025, NO FAKES Act of 2026 / S. 4591 H.R. 10025, Preventing Abuse of Digital Replicas Act Proposals for blocking foreign piracy websites, including H.R. 10364, American Copyright Protection Act of 2026, and S. 5529/H.R. 10575, DEFEND IP Act of 2026 S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025 S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 7140, Customer Legal Ease and Relief (CLEAR) Act
Client expense: $1,424,847 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Patent Protection and IP issues generally. S. 1546, Patent Eligibility and Restoration Act (PERA) HR 3152, Patent Eligibility and Restoration Act (PERA) S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) HR 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL)
Client expense: $750,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Issues related to intellectual property, including the NO FAKES Act (S. 1367), counterfeits, music licensing, and issues related to patent reform, International Trade Commission patent investigations, intermediary liability, and patent reform, including the RESTORE Patents Act (H.R. 1574 / S. 708), the Patent Eligibility Restoration (PERA) Act (H.R. 3152 / S. 1546), and the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R. 3160 / S. 1553).
Client expense: $4,490,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Patent & Trademark Office (PTO), SENATE
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2026 · third_quarter · Copyright/Patent/Trademark
S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues
Client expense: $7,040,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues
Client expense: $1,530,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. H.R. 9681, Fair Seeds for Farmers Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act. S. 5104, Fair Seeds for Farmers Act.
Client expense: $1,710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Client expense: $3,150,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: Not reported · Firm income: $70,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, White House Office
2026 · third_quarter · Copyright/Patent/Trademark
Intellectual property and patent issues; Standard Essential Patents; Intellectual Property/Patent enforcement at the International Trade Commission; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; Export Control issues
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
S. 43: Skinny Labels, Big Savings Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform
Client expense: $840,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2026 · third_quarter · Copyright/Patent/Trademark
Issues related to patent rights and patent enforcement; Issues related to H.R. 3160/S. 1553 - PREVAIL Act; Issues related to H.R. 3152/S. 1546 - Patent Eligibility Restoration Act of 2025; Issues related to H.R. 1574/S. 708 - RESTORE Patent Rights Act of 2025; Issues related to Section 337; H.R. 8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027; Issues related to the NPRM on Revision to Rules of Practice Before the Patent Trial and Appeal Board.
Client expense: Not reported · Firm income: $80,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Client expense: Not reported · Firm income: $610,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
H.R. 5811: Restoring Americas Leadership in Innovation Act of 2025; All provisions of the bill; H.R. 5819: Balancing Incentives Act of 2025; All provisions of the bill; S. 708 / HR. 1574 RESTORE Patent Rights Act of 2025: All provisions of the bill; S. 1546 / HR. 3152 Patent Eligibility Restoration Act of 2025: All provisions of the bill; S. 1553 / HR. 3160 PREVAIL Act: All provisions of the bill.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
Issues relating to the the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) (H.R. 3152) and Patent Eligibility Restoration Act (PERA) (S. 1546) patent legislation
Client expense: $340,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · third_quarter · Copyright/Patent/Trademark
S. 708 and H.R. 1534 -- RESTORE Patent Rights Act of 2025 -- issues related to injunctions for patent infringement S. 1546 and H.R. 3152 -- Patent Eligibility Restoration Act -- related to clarifications of Section 101 of patent law S. 1553 and H.R. 3160 -- PREVAIL Act (Promoting and Respecting Economically Vital American Innovation Leadership Act -- related to reforms of the Patent Trials and Appeals Board at the US Patent and Trademark Office Teleconference with OIRA and USPTO re: Revision to Rules of Practice before the Patent Trial and Appeals Board Extension of PTO's fee-sharing authority which expired in September 2026 Restrictions in federal research grants that could lead to payments to government
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, White House Office
2026 · third_quarter · Copyright/Patent/Trademark
H.R. 10575/S. 5529, the Deterring Extraterritorial Foreign Exploitation of Networks Damaging Intellectual Property (DEFEND IP) Act of 2026 S. 5104/H.R. 9681, Fair Seeds for Farmers Act H.R. 10204, Legislative Branch Agencies Clarification Act H.R 10364 American Copyright Protection Act of 2026 H.R. 10026, Honoring Circuit Judge Pauline Newman Act of 2026 H.R. 10025, Preventing Abuse of Digital Replicas Act H.R. 7140, Customer Legal Ease and Relief Act (CLEAR Act) H.R. 5811, Restoring Americas Leadership in Innovation Act of 2025 S. 3517, the Visual Artists Copyright Reform Act of 2025 H.R. 6517, To modify the appointment process for the Librarian of Congress, the Comptroller General, and the Director of the Government Publishing Office, and for other purposes H.R. 6028, Legislative Branch Agencies Clarification Act S. 1546/H.R. 3152, Patent Eligibility Restoration Act (PERA) of 2025 S. 1553/ H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) S. 1833/H.R. 3539, Leadership in CET Act S. 2677/H.R. 4930, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade S. 2455, TRAIN Act S. 2276/H.R. 3269, ETHIC Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 890, A bill to amend title 35, United States Code, to prevent double patenting, and for other purposes. H.R.1109, the Litigation Transparency Act of 2025 H.R. 2675, Protecting Our Courts from Foreign Manipulation Act of 2025 S. 1367/H.R. 5794, NO FAKES H.R 791, Foreign Anti-Digital Piracy Act (FADPA) S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 1041, Affordable Prescriptions for Patients Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 6485/S. 43, Skinny Labels, Big Savings Act Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Operations
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2026 · third_quarter · Copyright/Patent/Trademark
H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.
Client expense: $770,000 · Firm income: Not reported
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2026 · third_quarter · Health Issues
H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce programs under title VII of the Public Health Service Act H.R.7961 - Physicians and the Healthcare Workforce Act S.4086 - A bill to establish protections for health care providers who raise concerns about the quality of health care services, and for other purposes S.4039 - Professional Degree Access Restoration Act H.R.7884 - To amend the Internal Revenue Code of 1986 to provide a tax credit to health care professionals that provide health care services in qualifying facilities, and for other purposes; S.3908 - SOS: Sustaining Outpatient Services Act H.R.7686 - To recognize the importance of clinical roles of locum tenens physicians, and for other purposes H.R.7520 - Efficiency Adjustment Delay Act S.3762 - Prior Authorization Relief Act H.R.7118 - Genomic Answers for Childrens Health Act H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy HR 6371 - budget neutrality bill S. 1546/H.R. 3152 The Patent Eligibility Restoration Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 Issues relating to regulation of laboratory diagnostics CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to public health Conrad 30 Physician Workforce Optimization Act (S. 4637) H.R.9645 - Health Care Price Certainty for All Americans Act H.R. 9693 - The Patients First Act S 5180 Provider Reimbursement Stability Act S 5062 - FAIR DME Appeals Act H.R. 8500 / S. 5745 - Timely Access to Coverage Decisions Act ROOT Act HR 8890 the Enhancing CLIA Act
Client expense: $203,130 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Copyright/Patent/Trademark
S. 708/H.R. 1574, Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive Patent Rights (RESTORE) Act of 2025; S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025; S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act; Issues related to the International Trade Commission (ITC); Issues related to Intellectual Property Right and Patents.
Client expense: $570,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 1367/H.R.2794, NO FAKES Act of 2025, NO FAKES Act of 2026 / S.4591 Proposals for blocking foreign piracy websites S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025 S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 7140, Customer Legal Ease and Relief (CLEAR) Act
Client expense: $1,396,909 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---Oversight Pharmacy Benefit Managers Artificial Intelligence (AI) Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---28 U.S.C. 1498 - Patent and copyright cases Data Privacy ---H.R.8413: SECURE Data Act ---Implementation of BIOSECURE Act Drug Patenting ---H.R.3160/S.1553: PREVAIL Act ---H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act ---H.R.9142: Prohibiting Adversarial Patents Act of 2026 ---S.43/H.R.6485: Skinny Labels, Big Savings Act ---S.527: Prescription Pricing for the People Act ---S.1041: Affordable Prescriptions for Patients Act ---S.1095: Stop STALLING Act ---S.1096: Preserve Access to Affordable Generics and Biosimilars Act ---S.1097: Interagency Patent Coordination and Improvement Act of 2025 ---S.1546/H.R.3152: Patent Eligibility Restoration Act (PERA) ---S.2658: Medication Affordability and Patient Integrity Act ---S.3014: Ensuring Timely Access to Generics Act of 2025 ---Department of Commerce Patent Valuation Fee Proposal ---Patent Litigation Reform ---Patent Tax/fees ---PTAB Reform ---Restrictions on Intellectual Property Rights ---Section 101 Modernization Foreign Drug Data Protection Law ---Implementation of BIOSECURE Act Intellectual Property Enforcement ---China
Client expense: $2,360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Treasury, Dept of
2026 · second_quarter · Copyright/Patent/Trademark
Patent Protection and IP issues generally. S. 1546, Patent Eligibility and Restoration Act (PERA) HR 3152, Patent Eligibility and Restoration Act (PERA) S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) HR 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL)
Client expense: $720,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Discussions regarding automotive right to repair efforts (H.R.1566 - Right to Equitable and Professional Auto Industry Repair Act; entire bill) Discussions regarding several patent bills, including: Patent Eligibility Restoration Act (PERA; S.1546 and H.R. 3152) and Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL; S. 1553; HR 3160) (entire bills) Discussions regarding right to repair efforts in HR 8800 (Sec 861) and S 4784 (Sec 804), the National Defense Authorization Act for FY 2027
Client expense: $1,142,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
H.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. H.R.3152/S.1546: Patent Eligibility Restoration Act of 2025. H.R.3269/S.2276: Eliminating Thickets to Increase Competition (ETHIC) Act. S.2658: Medication Affordability and Patent Integrity Act. S.1041: Affordable Prescriptions for Patients Act. S.1096: Preserve Access to Affordable Generics and Biosimilars Act. H.R.6485/S.43: Skinny Labels, Big Savings Act. PTO rulemaking on inter partes review. H.R.5811: Restoring Americas Leadership in Innovation Act of 2025 (RALIA Act). Settled expectations discretionary denials.
Client expense: $870,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2026 · second_quarter · Copyright/Patent/Trademark
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Client expense: Not reported · Firm income: $450,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform. H.R. 1574, RESTORE Patent Rights Act of 2025. H.R. 3152, Patent Eligibility Restoration Act of 2025. H.R. 3160, PREVAIL Act. H.R. 3269, ETHIC Act. S. 708, RESTORE Patent Rights Act of 2025. S. 1546, Patent Eligibility Restoration Act of 2025. S. 1553, PREVAIL Act. S. 2276, ETHIC Act.
Client expense: $1,820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Issues related to intellectual property, including the NO FAKES Act (S. 1367), counterfeits, music licensing, and issues related to patent reform, International Trade Commission patent investigations, intermediary liability, and patent reform, including the RESTORE Patents Act (H.R. 1574 / S. 708), the Patent Eligibility Restoration (PERA) Act (H.R. 3152 / S. 1546), and the Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R. 3160 / S. 1553).
Client expense: $4,360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Economic Council (NEC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2026 · second_quarter · Copyright/Patent/Trademark
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Client expense: $2,440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues
Client expense: $7,360,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S. 1097/H.R. 4570 - Interagency Patent Coordination and Improvement Act of 2025. S. 43/H.R. 6485 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - Eliminating Thickets to Increase Competition (ETHIC) Act. H.R. 3160/S. 1533 - The Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
H.R. 7140, Customer Legal Ease and Relief Act (CLEAR Act) H.R. 5811, Restoring Americas Leadership in Innovation Act of 2025 S. 3517, the Visual Artists Copyright Reform Act of 2025 H.R. 6517, To modify the appointment process for the Librarian of Congress, the Comptroller General, and the Director of the Government Publishing Office, and for other purposes H.R. 6028, Legislative Branch Agencies Clarification Act S. 1546/H.R. 3152, Patent Eligibility Restoration Act (PERA) of 2025 S. 1553/ H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) S. 1833/H.R. 3539, Leadership in CET Act S. 2677/H.R. 4930, To expand the sharing of information with respect to suspected violations of intellectual property rights in trade S. 2455, TRAIN Act S. 2276/H.R. 3269, ETHIC Act H.R. 1566, the Right to Equitable and Professional Auto Industry Repair (REPAIR) Act H.R. 890, A bill to amend title 35, United States Code, to prevent double patenting, and for other purposes. H.R.1109, the Litigation Transparency Act of 2025 H.R. 2675, Protecting Our Courts from Foreign Manipulation Act of 2025 S. 1367/H.R. 5794, NO FAKES H.R 791, Foreign Anti-Digital Piracy Act (FADPA) S. 1097, Interagency Patent Coordination and Improvement Act of 2025 S. 1096, Preserve Access to Affordable Generics and Biosimilars Act S. 1041, Affordable Prescriptions for Patients Act S. 708/H.R. 1574, RESTORE Patent Rights Act of 2025 H.R. 6485/S. 43, Skinny Labels, Big Savings Act Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Operations
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform
Client expense: $1,410,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
2026 · second_quarter · Copyright/Patent/Trademark
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act
Client expense: Not reported · Firm income: $70,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, White House Office
2026 · second_quarter · Copyright/Patent/Trademark
Intellectual property and patent issues; Standard Essential Patents; Intellectual Property/Patent enforcement at the International Trade Commission; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; Export Control issues
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Issues related to patent enforcement; Issues related to H.R. 3160/S. 1553 - PREVAIL Act; Issues related to H.R. 3152/S. 1546 - Patent Eligibility Restoration Act of 2025; Issues related to H.R. 1574/S. 708 - RESTORE Patent Rights Act of 2025.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Issues related to patent reform legislation; Issues related to H.R. 3152/S. 1546 - Patent Eligibility Restoration Act of 2025.
Client expense: Not reported · Firm income: $80,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 708/H.R. 1574, Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive Patent Rights (RESTORE) Act of 2025; S. 1546/H.R. 3152, Patent Eligibility Restoration Act of 2025; S. 1553/H.R. 3160, Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act; Issues related to Intellectual Property Right and Patents.
Client expense: $570,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
Issues relating to the the Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL) (H.R. 3152) and Patent Eligibility Restoration Act (PERA) (S. 1546) patent legislation
Client expense: $320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues
Client expense: $890,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Copyright/Patent/Trademark
H.R. 5811: Restoring Americas Leadership in Innovation Act of 2025; All provisions of the bill; H.R. 5819: Balancing Incentives Act of 2025; All provisions of the bill; S.708 / HR.1574 RESTORE Patent Rights Act of 2025: All provisions of the bill; S.1546 / HR.3152 Patent Eligibility Restoration Act of 2025: All provisions of the bill; S.1553 / HR.3160 PREVAIL Act: All provisions of the bill.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
H.R.3152/S.1546: Patent Eligibility Restoration Act
Client expense: Not reported · Firm income: $70,500
Government targets: SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 708 and H.R. 1534 -- RESTORE Patent Rights Act of 2025 -- issues related to injunctions for patent infringement S. 1546 and H.R. 3152 -- Patent Eligibility Restoration Act -- related to clarifications of Section 101 of patent law S. 1553 and H.R. 3160 -- PREVAIL Act (Promoting and Respecting Economically Vital American Innovation Leadership Act -- related to reforms of the Patent Trials and Appeals Board at the US Patent and Trademark Office Executive Orders to tax or require royalty sharing of patented inventions Revision to Rules of Practice Before the Patent Trial and Appeals Board -- NPRM Docket No. PTO-P-2025-0025 Need for extension of PTO's fee-sharing authority which expires in September 2026 Restrictions in federal research grants that could lead to payments to government
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2026 · second_quarter · Health Issues
H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce programs under title VII of the Public Health Service Act H.R.7961 - Physicians and the Healthcare Workforce Act S.4086 - A bill to establish protections for health care providers who raise concerns about the quality of health care services, and for other purposes S.4039 - Professional Degree Access Restoration Act H.R.7884 - To amend the Internal Revenue Code of 1986 to provide a tax credit to health care professionals that provide health care services in qualifying facilities, and for other purposes; S.3908 - SOS: Sustaining Outpatient Services Act H.R.7686 - To recognize the importance of clinical roles of locum tenens physicians, and for other purposes H.R.7520 - Efficiency Adjustment Delay Act S.3762 - Prior Authorization Relief Act H.R.7118 - Genomic Answers for Childrens Health Act H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy HR 6371 - budget neutrality bill S. 1546/H.R. 3152 The Patent Eligibility Restoration Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 Issues relating to regulation of laboratory diagnostics CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to public health
Client expense: $180,107 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Copyright/Patent/Trademark
S. 1553 / H.R. 3160 PREVAIL Act S. 1546 / H.R. 3152 Patent Eligibility Restoration Act of 2025 (PERA) S. 1379 / H.R. 1566 REPAIR Act S. 2209 / H.R. 5155 Warrior Right to Repair Act of 2025 S. 4784 / H.R. 8800 National Defense Authorization Act S. 2658 Medication Affordability and Patent Integrity Act S. 43 / H.R. 6485 Skinny Labels, Big Savings Act S. 2276 / H.R. 3269 ETHIC Act (Eliminating Thickets to Increase Competition Act) H.R. 7015: Protecting Third Party Litigation Funding From Abuse Act S. 3826: Litigation Funding Transparency Act of 2026 H.R. 7389: Motor Vehicle Modernization Act of 2026 35 U.S.C. 5: Patent Public Advisory Committee (PPAC) and the Trademark Public Advisory Committee (TPAC) 35 U.S.C. 10: USPTO Fee-Setting Authority 15 U.S.C. 1125(d): Anti-Cybersquatting Consumer Protection Act
Client expense: $50,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office, U.S. International Trade Commission (ITC), U.S. Trade Representative (USTR)
2026 · first_quarter · Health Issues
H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes S.4110 - A bill to revise and extend health workforce programs under title VII of the Public Health Service Act H.R.7961 - Physicians and the Healthcare Workforce Act S.4086 - A bill to establish protections for health care providers who raise concerns about the quality of health care services, and for other purposes S.4039 - Professional Degree Access Restoration Act H.R.7884 - To amend the Internal Revenue Code of 1986 to provide a tax credit to health care professionals that provide health care services in qualifying facilities, and for other purposes; S.3908 - SOS: Sustaining Outpatient Services Act H.R.7686 - To recognize the importance of clinical roles of locum tenens physicians, and for other purposes H.R.7520 - Efficiency Adjustment Delay Act S.3762 - Prior Authorization Relief Act H.R.7118 - Genomic Answers for Childrens Health Act H.R. 1, the One Big, Beautiful Bill Act Improving seniors' timely access to care act (S. 1816 / H.R. 3514) Genomic Data Protection Act Tariffs PAMA reform S 1399, the Health Tech Investment Act H.R. 3580, the Oversight of Medicare Billing Code Cost Act S. 1916 - Protect Genetic information after bankruptcy S 1830 - HHS has no authority to regulate the practice of medicine LCD legislation HR2389/S1302 - Resident Physician Shortage Reduction Act S2333 - Public Health Workforce Loan Repayment Act S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act CLIA Waiver CURES 2.0 To prevent across-the-board direct spending cuts HR 5392, the Timely Access to Coverage Decisions Act of 2023 Remote digital telepathology HR 4527 - HEALTH DATA Act Primary Care and Health Workforce Expansion Act Gene Therapy HR 6371 - budget neutrality bill S. 1546/H.R. 3152 The Patent Eligibility Restoration Act Cures 2.1 S. 4935, Physician Fee Stabilization Act Medical Lab Personnel Shortage Relief Act S. 1380 - SPARC Act S. 942/H.R. 2028 - REDI Act H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025 Issues relating to regulation of laboratory diagnostics CDC Division of Cancer Prevention and Control and cancer registries appropriations S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act H.R.5371 - Continuing Appropriations and Extensions Act, 2026 S 2420 / H.R. 4710 - No Surprises Act Enforcement Act S 2793 - Ensuring Access to Essential Providers Act of 2025 H.R. 5582 / S 2355 - Patients Deserve Price Tags Act Issues related to public health
Client expense: $305,901 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Copyright/Patent/Trademark
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. H.R. 6485 & S.43 Skinny Labels, Big Savings Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE